Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza viruses could pose huge challenges to our healthcare system. We evaluated the efficiency of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-time PCR Kit (PowerChek; Kogene Biotech, Seoul, Korea) in comparability with the BioFire Respiratory Panels 2 and a couple of.1 (RP2 and RP2.1; bioMérieux, Marcy l’Étoile, France), utilizing 147 nasopharyngeal swabs.
The restrict of detection (LOD) of the PowerChek assay was decided utilizing SARS-CoV-2, influenza A, and B RNA requirements. The LOD values of the PowerChek assay for SARS-CoV-2 and influenza A and B have been 1.12, 1.24, and 0.61 copies/μL, respectively.
The constructive and damaging p.c agreements of the PowerChek assay in contrast with RP2 and RP2.1 have been 97.5% (39/40) and 100% (107/107) for SARS-CoV-2; 100% (39/39) and 100% (108/108) for influenza A; and 100% (35/35) and 100% (112/112) for influenza B, respectively. The efficiency of the PowerChek assay was corresponding to that of RP2 and RP2.1 for detecting SARS-CoV-2 and influenza A and B, suggesting its use in diagnosing SARS-CoV-2 and influenza infections.

Development and Evaluation of AccuPower COVID-19 Multiplex Real-Time RT-PCR Kit and AccuPower SARS-CoV-2 Multiplex Real-Time RT-PCR Kit for SARS-CoV-2 Detection in Sputum, NPS/OPS, Saliva and Pooled Samples

  1. Rapid and correct detection of the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is important for the profitable management of the present world COVID-19 pandemic. The real-time reverse transcription polymerase chain response (Real-time RT-PCR) is the most generally used detection approach.
  2. This analysis describes the growth of two novel multiplex real-time RT-PCR kits, AccuPower® COVID-19 Multiplex Real-Time RT-PCR Kit (NCVM) particularly designed to be used with the ExiStation™48 system (comprised of ExiPrep™48 Dx and Exicycler™96 by BIONEER, Korea) for pattern RNA extraction and PCR detection, and AccuPower® SARS-CoV-2 Multiplex Real-Time RT-PCR Kit (SCVM) designed to be appropriate with producers’ on-market PCR devices.
  3. The restrict of detection (LoD) of NCVM was 120 copies/mL and the LoD of the SCVM was 2 copies/μL for each the Pan-sarbecovirus gene and the SARS-CoV-2 gene. The AccuPower® kits demonstrated excessive precision with no cross reactivity to different respiratory-related microorganisms.
  4. The scientific efficiency of AccuPower® kits was evaluated utilizing the following scientific samples: sputum and nasopharyngeal/oropharyngeal swab (NPS/OPS) samples.
  5. Overall settlement of the AccuPower® kits with a Food and Drug Administration (FDA) accredited emergency use licensed business package (STANDARD™ M nCoV Real-Time Detection package, SD BIOSENSOR, Korea) was above 95% (Cohen’s kappa coefficient ≥ 0.95), with a sensitivity of over 95%.
  6. The NPS/OPS specimen pooling experiment was carried out to confirm the usability of AccuPower® kits on pooled samples and the outcomes confirmed better than 90% settlement with particular person NPS/OPS samples.
  7. The scientific efficiency of AccuPower® kits with saliva samples was additionally in contrast with NPS/OPS samples and demonstrated over 95% settlement (Cohen’s kappa coefficient > 0.95). This examine reveals the BIONEER NCVM and SCVM assays are comparable with the present commonplace affirmation assay and are appropriate for efficient scientific administration and management of SARS-CoV-2.

Leave a Reply

Your email address will not be published.